nicotine addiction

Using pathway and network analyses, researchers identified overlapping genes and biological processes behind smoking and schizophrenia, including new candidate genes.

NEW YORK (GenomeWeb News) – Bioinformatics and data analysis firm BioRealm said on Wednesday it has received a Small Business Innovation Research contract from the National Institute on Drug Abuse to develop a genetic screening tool for tobacco addiction and treatment approaches.

A team led by researchers at Washington University in St. Louis has shown that genetic variants associated with nicotine dependence and smoking quantity are also predictive of whether patients will benefit from the use of smoking cessation medications.

The company has won an SBIR grant from NIDA to develop a systems biology database and analysis tool for nicotine addiction.

With this new funding, the NIH hopes to continue PGx research in existing focus areas of cancer, heart disease, asthma, and nicotine addiction, and also to expand into new areas, including rheumatoid arthritis and bipolar disorder.

An ever-increasing number of studies are looking at the role that genetics and epigenetics play in the predisposition for — and treatment of — alcohol abuse, nicotine dependence, and drug addiction.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.